News
Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback